Abstract
Background Low birthweight (LBW) is the leading cause of neonatal mortality and hospitalization worldwide. This study specifically aimed to: 1) determine the frequency of a) neonatal deaths and 2) assess their association with LBW in Northern Uganda.
Methods A cohort study, nested in the Survival Pluss cluster randomized trial (NCT02605369), was conducted from January 2018 to February 2019 in Lira district, Northern Uganda. Out of 1877 pregnant women, 1556 live-born infants had their birthweight measured and were followed up to 28 days after birth. Generalized estimation equation regression models of the Poisson family with a log link were used to calculate the risk ratios between LBW and death.
Results The risk of neonatal death was: 21/1,556 or 13.5 (95% CI: 8.8 – 20.6) per 1,000 live births. The respective sex and cluster adjusted proportion of neonatal death per 1000 live births among LBW, normal weight and not-weighed infants were 103 (95% CI: 47.2 – 212), 5.4 (95% CI: 2.1 – 13.9) and 167 (95% CI: 91.1-285). Compared to normal birthweight, LBW and not-weighed infants were each associated with a 20- and 30-folds increased risk of neonatal death.
Conclusion In this community-based cohort study in Northern Uganda, neonatal mortality was 13.5/1000 live births. In the LBW and not-weighed groups, the risk of a neonatal death were more than twenty-times that of non-LBW infants. Efforts to reduce the number of LBW infants and/or prevent adverse outcomes in this patient group urgently are needed. In addition, all babies with should have birthweight recorded to facilitate early risk identification and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There are no conflicts of interest be it financial or otherwise from the funder
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Makerere College of Health Sciences School of Medicine Research and Ethics Committee (SOMREC)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Unrestricted data access can be obtained from the corresponding author on reasonable request.
